Patient characteristics by indication for instituting second-line therapy
| Patient characteristics . | Group 1 . | Group 2 . | Group 3 . | Group 4 . | Group 5 . | P . |
|---|---|---|---|---|---|---|
| No documented R/P (N = 24) . | Hematologic . | Organ R/P only . | Both hematologic and organ R/P (N = 72) . | Suboptimal response (N = 10) . | ||
| R/P only (N = 53) . | (N = 76) . | |||||
| Age, median (IQR) | 57 (50-70) | 60 (53-64) | 57 (53-62) | 58 (49-65) | 54 (50-61) | .43 |
| Male sex, n (%) | 15 (62) | 30 (57) | 54 (71) | 43 (60) | 5 (50) | .39 |
| Year of ASCT, median (IQR) | 2008 (2004-2013) | 2006 (2003-2010) | 2007 (2004-2010) | 2005 (2003-2007) | 2009 (2007-2011) | .007 |
| Diagnosis median dFLC, mg/dL (IQR) | 19.5 (5.4, 67.4) | 38.0 (13.1, 90.3) | 9.4 (5.1, 26.4) | 24.6 (11.9, 82.2) | 24.8 (13.6, 46.5) | <.001 |
| Diagnosis dFLC <5 mg/dL, % | 20 | 11 | 24 | 7 | 10 | .08 |
| AL stage >2, n (%)* | ||||||
| 2004 stage† | 0 (0) | 8 (20) | 8 (14) | 8 (17) | 2 (22) | .10 |
| 2012 stage‡ | 1 (5) | 11 (28) | 15 (26) | 12 (26) | 3 (33) | .18 |
| Organs >2, n (%) | 2 (8) | 5 (9) | 13 (17) | 11 (15) | 0 (0) | .26 |
| Post-ASCT CR, n (%) | 3 (12) | 18 (33) | 15 (27) | 19 (35) | 0 (0) | .06 |
| Post-ASCT ≥VGPR, n (%) | 10 (50) | 35 (67) | 47 (66) | 37 (54) | 0 (0) | <.001 |
| Post-ASCT ≥PR, n (%) | 21 (88) | 48 (91) | 60 (79) | 62 (86) | 4 (40) | .009 |
| ASCT organ response, n (%) | 7 (29) | 29 (55) | 29 (38) | 35 (49) | 3 (30) | .13 |
| Months from ASCT to second-line (median, IQR) | 13.3 (6.8-24.4) | 31.3 (17.4-60.2) | 16.0 (9.3-38.2) | 29.3 (15.2-51.7) | 3.7 (3.2-9.8) | <.001 |
| Novel agent in second-line therapy, n (%) | 16 (67) | 44 (83) | 49 (65) | 51 (73) | 9 (90) | .12 |
| Second-line therapy post-2009, n (%) | 15 (63) | 31 (60) | 39 (51) | 31 (43) | 6 (60) | .30 |
| Median dFLC at second-line, mg/dL (IQR) | 5.7 (2.7-17.7) | 11.6 (6.7-21.8) | 3.2 (2.0-7.3) | 15.4 (9.1-40.7) | 12.8 (8.4-21.3) | <.001 |
| dFLC at second-line ≥5 mg/dL, n (%) | 13 (62) | 44 (85) | 25 (36) | 63 (89) | 8 (80) | <.001 |
| “Subtle” hematologic R/P or more, n (%) | 10 (42) | 53 (100) | 17 (22) | 72 (100) | 1 (10) | <.001 |
| Patient characteristics . | Group 1 . | Group 2 . | Group 3 . | Group 4 . | Group 5 . | P . |
|---|---|---|---|---|---|---|
| No documented R/P (N = 24) . | Hematologic . | Organ R/P only . | Both hematologic and organ R/P (N = 72) . | Suboptimal response (N = 10) . | ||
| R/P only (N = 53) . | (N = 76) . | |||||
| Age, median (IQR) | 57 (50-70) | 60 (53-64) | 57 (53-62) | 58 (49-65) | 54 (50-61) | .43 |
| Male sex, n (%) | 15 (62) | 30 (57) | 54 (71) | 43 (60) | 5 (50) | .39 |
| Year of ASCT, median (IQR) | 2008 (2004-2013) | 2006 (2003-2010) | 2007 (2004-2010) | 2005 (2003-2007) | 2009 (2007-2011) | .007 |
| Diagnosis median dFLC, mg/dL (IQR) | 19.5 (5.4, 67.4) | 38.0 (13.1, 90.3) | 9.4 (5.1, 26.4) | 24.6 (11.9, 82.2) | 24.8 (13.6, 46.5) | <.001 |
| Diagnosis dFLC <5 mg/dL, % | 20 | 11 | 24 | 7 | 10 | .08 |
| AL stage >2, n (%)* | ||||||
| 2004 stage† | 0 (0) | 8 (20) | 8 (14) | 8 (17) | 2 (22) | .10 |
| 2012 stage‡ | 1 (5) | 11 (28) | 15 (26) | 12 (26) | 3 (33) | .18 |
| Organs >2, n (%) | 2 (8) | 5 (9) | 13 (17) | 11 (15) | 0 (0) | .26 |
| Post-ASCT CR, n (%) | 3 (12) | 18 (33) | 15 (27) | 19 (35) | 0 (0) | .06 |
| Post-ASCT ≥VGPR, n (%) | 10 (50) | 35 (67) | 47 (66) | 37 (54) | 0 (0) | <.001 |
| Post-ASCT ≥PR, n (%) | 21 (88) | 48 (91) | 60 (79) | 62 (86) | 4 (40) | .009 |
| ASCT organ response, n (%) | 7 (29) | 29 (55) | 29 (38) | 35 (49) | 3 (30) | .13 |
| Months from ASCT to second-line (median, IQR) | 13.3 (6.8-24.4) | 31.3 (17.4-60.2) | 16.0 (9.3-38.2) | 29.3 (15.2-51.7) | 3.7 (3.2-9.8) | <.001 |
| Novel agent in second-line therapy, n (%) | 16 (67) | 44 (83) | 49 (65) | 51 (73) | 9 (90) | .12 |
| Second-line therapy post-2009, n (%) | 15 (63) | 31 (60) | 39 (51) | 31 (43) | 6 (60) | .30 |
| Median dFLC at second-line, mg/dL (IQR) | 5.7 (2.7-17.7) | 11.6 (6.7-21.8) | 3.2 (2.0-7.3) | 15.4 (9.1-40.7) | 12.8 (8.4-21.3) | <.001 |
| dFLC at second-line ≥5 mg/dL, n (%) | 13 (62) | 44 (85) | 25 (36) | 63 (89) | 8 (80) | <.001 |
| “Subtle” hematologic R/P or more, n (%) | 10 (42) | 53 (100) | 17 (22) | 72 (100) | 1 (10) | <.001 |
Unless otherwise stated, characteristics are at diagnosis.
R/P, relapse or progression.
Data available for only 172 patients.
2004 stage is defined by troponin T and NT pro-BNP threshold (0.035 ng/mL and 332 pg/mL). Stage I, both below threshold; stage II, 1 above threshold; stage II, both above threshold.19
2012 stage is defined by troponin T, NT pro-BNP, and dFLC threshold (0.05 ng/mL, 1800 pg/mL, and 18 mg/dL, respectively). Stage I, all below threshold; stage II, 3 below threshold; stage II, 2 below threshold; stage IV, all above threshold.20